A New Wave of Progress in the Treatment of Renal Cell Carcinoma: Highlights from ASCO GU 2023 and Beyond - Episode 4

Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

, , ,

Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.

EP. 1: Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)
EP. 2: Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC
EP. 3: Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER
Now Viewing
EP. 4: Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC
EP. 5: Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC
EP. 6: Treatment Approaches for Patients with RCC and Bone Metastases
EP. 7: Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment
EP. 8: Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial
EP. 9: Updates in the Adjuvant Treatment of Metastatic RCC
EP. 10: Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC
EP. 11: Preferred Treatment Regimens for Refractory RCC
EP. 12: Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC
EP. 13: Genetic Counseling for Patients with Non-Clear Cell RCC